Orkin's research led to a gene therapy for sickle cell disease and beta-thalassemia; it is the first Food and Drug Administration-approved CRISPR-based gene therapy.

Positive findings from a clinical trial support further study of the investigational drug ifetroban to treat cardiac complications, the leading cause of death in patients with DMD.

Long-term trajectories of irregular sleep durations outside the optimal range (more or less than the healthy duration of seven to nine hours of sleep per night) increased the risk of death from all causes by as much as 29%.

The patients exhibited lower heart rates, reported high satisfaction with virtual reality and experienced no feelings of cybersickness.

Sarah Tishkoff described her groundbreaking research during a talk titled “African Evolutionary Genomics: Reconstructing Human Evolution and the Genetic Basis of Complex Adaptive Traits.”

The approach will address “bottlenecks” that slow the traditional antibody discovery process, and it aims to make it possible to generate monoclonal antibody therapies against any target of interest.

By 2017, on the back of the opioid crisis, the rate of neonatal opioid withdrawal syndrome in the U.S. was estimated to have reached 7.3 per 1000 deliveries. Meanwhile, many newborns exposed to opioids in utero never develop the syndrome and must undergo needless monitoring in the hospital after birth.